Vivimed Labs.

Why is Vivimed Labs Ltd falling/rising?

As of 08-Aug, Vivimed Labs Ltd's stock price is Rs. 5.06, showing a minor increase but facing significant downward pressure with a year-to-date decline of 71.30%. The stock's bearish trend is supported by poor financial health, negative EBITDA, and waning investor confidence, classifying it as a strong sell.

As of 08-Aug, Vivimed Labs Ltd's stock price is currently at Rs. 5.06, reflecting a slight increase of 0.02 (0.4%). However, despite this minor rise, the stock has been experiencing significant downward pressure over various time frames. Over the past week, the stock has declined by 2.13%, and in the last month, it has dropped by 10.12%. Year-to-date, the stock has plummeted by 71.30%, while the benchmark Sensex has only decreased by 7.89% during the same period.<BR><BR>Today's performance indicates that the stock hit a new 52-week low of Rs. 4.91, which further underscores its struggles. Additionally, the stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Investor participation has also waned, with delivery volume falling by 53.77% compared to the 5-day average, suggesting a lack of confidence among investors.<BR><BR>The company's financial health is a significant concern, as it has a negative book value and a high Debt to EBITDA ratio of -2.61 times, indicating a low ability to service its debt. Furthermore, the company has recorded a negative EBITDA of Rs. -154.63 crore, and its profits have fallen by 452% over the past year. These factors contribute to the stock being classified as risky and a strong sell, reflecting weak long-term fundamental strength and low profitability.<BR><BR>In summary, while there is a slight uptick in the stock price today, the overall trend and financial indicators suggest that Vivimed Labs Ltd is facing considerable challenges, leading to a predominantly falling stock trajectory.

Which are the latest news on Vivimed Labs.?

Should I buy, sell or hold Vivimed Labs Ltd?

When is the next results date for Vivimed Labs Ltd?

The next results date for Vivimed Labs Ltd is 17 July 2026.

The next results date for Vivimed Labs Ltd is scheduled for 17 July 2026.

How big is Vivimed Labs.?

As of 10th June, Vivimed Labs Ltd has a market capitalization of 53.00 Cr and reported Net Sales of 108.46 Cr, with a Net Profit loss of 45.41 Cr over the latest four quarters. As of March 2023, Shareholder's Funds were 39.42 Cr and Total Assets were 988.35 Cr.

As of 10th June, Vivimed Labs Ltd has a market capitalization of 53.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 108.46 Cr. However, it faced a loss of 45.41 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2023, where Shareholder's Funds amounted to 39.42 Cr and Total Assets were valued at 988.35 Cr.

Who are in the management team of Vivimed Labs.?

The management team of Vivimed Labs includes Santosh Varalwar (Managing Director), V Manohar Rao, Sandeep Varalwar, and S Raghunandan (Whole Time Directors), along with Subhash Varalwar (Non Executive Director), M Bhagvanth Rao, Nixon Patel, and Umanath Varahabhotla (Non Executive Independent Directors), and Yugandhar Kopparthi (Company Secretary & Compliance Officer). They are responsible for the company's strategic direction and operations.

The management team of Vivimed Labs includes the following individuals:<BR><BR>1. **Santosh Varalwar** - Managing Director<BR>2. **V Manohar Rao** - Whole Time Director<BR>3. **Subhash Varalwar** - Non Executive Director<BR>4. **Sandeep Varalwar** - Whole Time Director<BR>5. **S Raghunandan** - Whole Time Director<BR>6. **M Bhagvanth Rao** - Non Executive Independent Director<BR>7. **Nixon Patel** - Non Executive Independent Director<BR>8. **Umanath Varahabhotla** - Non Executive Independent Director<BR>9. **Yugandhar Kopparthi** - Company Secretary & Compliance Officer<BR><BR>This team plays a crucial role in guiding the company’s strategic direction and operations.

Who are the peers of the Vivimed Labs.?

Vivimed Labs. peers include Sun Pharma, Divi's Lab, Torrent Pharma, Cipla, Dr Reddy's Labs, Parabolic Drugs, ANG Lifesciences, Deccan Healthcar, and Unick Fix-A-Form. Sun Pharma and Dr Reddy's Labs show excellent management and capital structures, while Vivimed Labs. has below average ratings in these areas and lacks a 1-year return for comparison.

Peers: The peers of Vivimed Labs. are Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Dr Reddy's Labs, Parabolic Drugs, ANG Lifesciences, Deccan Healthcar, and Unick Fix-A-Form.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, and Dr Reddy's Labs, while Below Average management risk is found at Vivimed Labs., ANG Lifesciences, and Deccan Healthcar. Growth is Excellent at Sun Pharma.Inds., Good at Dr Reddy's Labs, Average at Torrent Pharma, and Below Average at Divi's Lab., Cipla, Vivimed Labs., ANG Lifesciences, and Unick Fix-A-Form, with Parabolic Drugs not qualifying. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is seen at Vivimed Labs., ANG Lifesciences, and Unick Fix-A-Form, with Parabolic Drugs also not qualifying.<BR><BR>Return Snapshot: Torrent Pharma has the highest 1-year return at 42.85%, while Cipla has the lowest at -8.67%. Vivimed Labs.' 1-year return is not available for comparison. Additionally, the six-month return is negative for Cipla and Dr Reddy's Labs.

What does Vivimed Labs. do?

Vivimed Labs Ltd manufactures specialty chemicals for the personal care, cosmetic, and pharmaceutical industries. As of December 2025, it reported net sales of 16 Cr and a net loss of 17 Cr, with a market cap of INR 53 Cr.

Overview:<BR>Vivimed Labs Ltd is engaged in the manufacturing of specialty chemicals primarily for the personal care and cosmetic industry, as well as pharmaceuticals, APIs, and formulations, operating within the pharmaceuticals and drugs industry and classified as a micro-cap company.<BR><BR>History:<BR>Vivimed Labs Ltd was incorporated in an unspecified year and has undergone various status changes. The latest quarterly results reported net sales and profit for the period ending December 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 16 Cr (Quarterly Results - Dec 2025)<BR>- Net Profit: -17 Cr (Quarterly Results - Dec 2025)<BR>- Market-cap: INR 53 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 9.51<BR>- Return on Equity: -833.41%<BR>- Price to Book: 1.32<BR><BR>Contact Details:<BR>- Address: Plot No 78-A, Kolhar Industrial Area Bidar Karnataka : 585403<BR>- Tel: 91-8482-232045<BR>- Email: yugandhar.kopparthi@vivimedlabs.com<BR>- Website: http://www.vivimedlabs.com